American Urological Association President Sushil S. Lacy, MD, said in prepared remarks that he was "outraged" by the report. "It is inappropriate and irresponsible to issue a blanket statement against PSA testing, particularly for at-risk populations such as African-American men," Lacy said. "Men who are in good health and have more than 10-15 years life expectancy should have the choice to be tested and not discouraged from doing so."
A similar statement was issued this week by the American Association of Clinical Urologists, which called the USPSTF recommendations "misleading and harmful." The major urological associations say the USPSTF ignored new studies supporting the value of PSA tests, and that the panel refused to address concerns they raised about the conclusions during the comment period. In addition, the urologists complain that there were no urologists or oncologists on the panel.
Siegel, who is also the president and CEO of Maryland-based Chesapeake Urology Associates, says urologists have long understood that the PSA test can lead to a high percentage of false positives, but he said that doesn't mean the test should be discounted.
"It is just a screening test, one of several things we look at when we decide whether a man needs a biopsy or not," he says.